- Arvinas Inc to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program Call TranscriptDec 06, 2023
- Arvinas Inc To Host ESMO Data Presentation Call TranscriptOct 22, 2023
- Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Arvinas Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Arvinas Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Arvinas Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Arvinas Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Arvinas Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Arvinas, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 01:30 PM TranscriptJan 11, 2023
- Arvinas Inc SABCS Event TranscriptNov 22, 2022
- Arvinas Inc at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Arvinas Inc at Citi BioPharma Conference TranscriptSep 08, 2022
- Arvinas Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Arvinas Inc at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Arvinas Inc to Discuss the Phase 1 Dose Escalation Data and Interim Data from the Phase 2 ARDENT Trial TranscriptFeb 17, 2022
- Arvinas Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Arvinas Inc ARV-471 Program Update Call TranscriptDec 10, 2021
- Arvinas Inc and Pfizer Inc Announce ARV-471 Collaboration- Conference Call TranscriptJul 22, 2021
- Arvinas Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Arvinas Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Arvinas Inc ASCO Data Conference Call TranscriptMay 29, 2020
- Arvinas Inc Conference Call TranscriptOct 23, 2019
Arvinas Inc to Discuss the Phase 1 Dose Escalation Data and Interim Data from the Phase 2 ARDENT Trial Transcript
Thank you for standing by, and welcome to the Arvinas ASCO GU data conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Jeff Boyle, Vice President of Investor Relations. Please go ahead.
Good morning, everyone, and thank you for joining us to discuss the ARV-110, which we now refer to as bavdegalutamide, Phase 1 dose escalation and interim ARDENT Phase 2 dose expansion trial results that will be presented later today at the ASCO GU conference.
Earlier this morning, we issued a press release highlighting the data, which can be accessed in the Investors section of our website at arvinas.com. With me this morning are: Arvinas President and Chief Executive Officer, John Houston; and Arvinas Chief Medical Officer, Ron Peck; Ian Taylor, our Chief Scientific Officer, will join for the Q&A portion of the call.
Before we begin, I would like to remind you that today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)